Indaptus Therapeutics is trading 11% down today at $1.75 as investors continue to lock in profits following a recent sharp rally.
- The move extends a period of weakness driven by profit-taking that began during Friday's and Monday's trading sessions.
- There are no new company-specific catalysts or regulatory updates this morning to account for the downward pressure.
- The stock's decline persists despite a broadly positive performance across the wider biotechnology sector.